Please login to the form below

Not currently logged in
Email:
Password:

AZ agrees cancer alliance with Immunocore

Medimmune subsidiary will work with biotech on encouraging patient's immune system to tackle tumours

AstraZeneca's Medimmune subsidiary announced a collaboration this morning with UK company Immunocore that will focus on the development of cancer therapeutics.

The two companies will work on new drug based on Immunocore's Immune Mobilising Monoclonal T-Cell Receptor against Cancer (ImmTAC) technology, which encourages a patient's own immune system to tackle tumours.

The deal potentially covers a number of targets, with AZ offering an upfront fee of $20m and up to $300m in development and milestone payments per programme, plus royalties if any of the therapies reach the market.

Immunocore also has collaborations in place with GlaxoSmithKline and Roche/Genentech, as well as its own melanoma therapy in phase II testing.

Article by
Phil Taylor

9th January 2014

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics